Fundraising Fox
/Companies
Sign in

Avidicure

6 known investors

Find your way into Avidicure

Each arrow is one introduction. Sign up to fill in the first one.

190 people can intro you to Robert

Ask Thomas de Vlaam to introduce you to Robert Friesen

You →Thomas · together at ProQR Therapeutics N.V. →Robert

Sign up to find every way you can get introduced to Avidicure

  • Your email: who you already know at Avidicure, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Avidicure team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a γδ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.

AI & Machine LearningBiotech

Founders & leadership

RFRobert Friesen
Robert FriesenCSO & Co-FounderRobert Friesen holds a Ph.D. in Biochemistry from the University of Texas Medical Branch and an M.S. in Biology from the University of Utrecht. He previously served as Vice President and Head of Biologics Research at Janssen R&D, where he led a team of over 200 scientists on biotherapeutic discovery and development, and held senior R&D roles at MorphoSys, Crucell, Ablynx, and Kiadis.

Investors · 6

EQT Life Sciences✓ confirmed by AvidicureLuxembourg · $11M – $66M

How we know: the company's own site · Not right? Tell us

BOMlisted by BOMTilburg · $540K – $5.8M

How we know: BOM's portfolio page · Not right? Tell us

Curie Capitallisted by Curie CapitalAmsterdam
Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M

How we know: Kurma Partners's portfolio page · the VCSheet dataset · Not right? Tell us

V-Bio Ventureslisted by V-Bio VenturesGhent · $270K – $2.2M

Funding

SEC filings, press & company announcements

$50M disclosed across 1 of 3 rounds · 2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Avidicure is included in the "Biotech Financing" report in Nature Biotechnology - Avidicure DEVavidicure.com · Jun 2025BioWorld News: Avidicure boosting immune activation with $50M seed round to advance novel antibody formats - Avidicure DEVavidicure.com · Jun 2025Avidicure to Present Preclinical Data from Lead Program at ASCO - Avidicure DEVavidicure.com · May 2025Avidicure Raises $50M in Seed Financingfinsmes.com · Apr 2025Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancerglobenewswire.com · Apr 2025

Frequently asked questions

What does Avidicure do?
Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases. Its lead program, AVC-S-201, is a γδ T cell-targeting antibody being developed for AML and other blood cancers and solid tumors.
Who founded Avidicure?
Avidicure was founded by Robert Friesen.
Who are Avidicure's investors?
Avidicure's investors include BioGeneration Ventures, EQT Life Sciences, BOM, Curie Capital, Kurma Partners, V-Bio Ventures.
How much funding has Avidicure raised?
Avidicure has disclosed $50M raised across 1 of its 3 known rounds.